Thromboembolic disease and hemostatic alterations in tumor-bearing dogs – A narrative review
Authors:
Open Access
- 5 June 2026
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Veterinary Science
- Vol. 13, 1818630
Abstract
Hemostatic dysfunction is a prevalent and significant complication in tumor-bearing dogs, driven by complex interactions between the tumor microenvironment and the host's coagulation system. This narrative review examines primary and secondary hemostatic alterations, fibrinolytic abnormalities, and prognostic indicators associated with hemostatic variables in canine lymphoma, carcinoma, and sarcoma. In lymphoma, the true prevalence of thromboembolic disease (TED) is unknown; clinically significant hemostatic alterations are typically associated with advanced stages, characterized by persistent hypercoagulability, or elevated D-dimer concentrations, and may be associated with a poor prognosis. Carcinomas are associated with TED, and hemostatic alterations are common, typically characterized by reactive thrombocytosis, hyperfibrinogenemia, and viscoelastic evidence of hypercoagulability. Sarcomas appear to be most associated with TED. Soft tissue sarcoma and osteosarcoma exhibit different hemostatic alterations and prognostic variables compared with hemangiosarcoma, and these differences are typically related to the stage of the disease. By synthesizing current evidence, recent advances, and key knowledge gaps, this review identifies the need to define tumor-specific hemostatic diagnostic profiles in tumor-bearing dogs and subsequently develop tailored thromboprophylaxis strategies. This may ultimately improve survival by enabling targeted management of hemostatic alterations and, potentially, by mitigating metastatic progression.Keywords
This publication has 145 references indexed in Scilit:
- Fibrinogen: A new player and target on the formation of pre-metastatic niche in tumor metastasisCritical Reviews in Oncology/Hematology, 2025
- External validation of the Khorana score for the prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysisInternational Journal of Nursing Studies, 2024
- Canine Cancer Cells Activate Platelets via the Platelet P2Y12 ReceptorJournal of Comparative Pathology, 2022
- Diagnosis of primary hyperfibrinolysis and in vitro investigation of the inhibitory effects of tranexamic acid in a group of dogs with sarcomas – A pilot studyResearch in Veterinary Science, 2021
- Anticoagulation Strategies in Patients With CancerJACC, 2019
- Platelets Inhibit Migration of Canine Osteosarcoma CellsJournal of Comparative Pathology, 2017
- Thrombin induces osteosarcoma growth, a function inhibited by low molecular weight heparin in vitro and in vivoCancer, 2011
- Retrospective survey of malignant lymphoma cases in the dog: clinical, therapeutical and prognostic featuresVeterinary Research Communications, 2008
- Low molecular weight heparin (LMWH) increases the efficacy of cisplatinum plus gemcitabine combination in advanced pancreatic cancerJournal of Surgical Oncology, 2006
- Effect of warfarin anticoagulation on survival in carcinoma of the lung, colon, head and neck, and prostate: Final Report of VA cooperative study # 75Cancer, 1984